Gastric Cancer
Conditions
Keywords
Conversion therapy
Brief summary
The prognosis of Extensive lymph nodes metastatic(ELM) gastric cancer is poor. Chemotherapy occasionally converts it to a resectable cancer. Previous studies showed patients with ELM gastric cancer may obtain a survival benefit from chemotherapy and subsequent curative surgery. The key of conversion therapy of ELMGC is the high response rate. Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the patients with GC. On the basis of our previous Ahead-G325 study, The purpose of this study is to investigate the efficacy and safety of S1/Paclitaxel chemotherapy plus Apatinib in the conversion therapys of ELM gastric cancer.
Detailed description
The investigators will apply SPA regimen for coversional therapy to abtain high response rate. Paclitaxel：150 mg/m2 i.v.3h , given on the first day. Apatinib, oral ,initial dose :425mg, QD, after meal ( try to take the medicine at the same time of the day ). Dose adjustment: Down-regulate the dosage to 250 mg per day at the first time. If the patient totally recovers from the toxic reaction after the regulation, we could up-regulate the dosage back to the former level. If the downregulation occurs again according to the protocol , then the up-regulation will be forbidden. S-1 dosage: According to the body surface area, the initial dosage of S-1 is decided by the following criteria. Take the medicine twice daily (after breakfast and supper) for 2 weeks, then suspend for 1 week. Preventive medication: To prevent serious allergic reaction of Paclitaxel, preventive medication should be given in advance. We usually give dexamethasone 20mg orally 12 and 6 hours before the Paclitaxel, and diphenhydramine (or something analogous) 50 mg, cimetidine 300mg (or ranitidine 50mg) I.V. 30-60 minutes before the Paclitaxel. Repeat the therapeutic schedule every 3 weeks. 3-4 cycles of neoadjuvant chemotherapy before surgery, stop Apatinib in the last cycle.4 cycles of adjuvant chemotherapy including S-1 and Apatinib 4 to 6 weeks after surgery.
Interventions
DRUGSPA
S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
Sponsors
Zhejiang Cancer Hospital
Fujian Cancer Hospital
The First Affiliated Hospital of Zhejiang Chinese Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* ELM gastric cancer as proven histologically under following condition: unable radical excision due to the abdominal aorta a2-b1 or extensive lymph nodes metastatic, * Definitely diagnosed as above stage of gastric cancer before operation via CT of MRI, ultrasonic endoscopy, PET-CT, or through the laparoscopic exploration if necessary * Untreated (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy) * Negative HER-2 state * ECOG(Eastern Cooperative Oncology Group): 0\ 2 * Age: 18\ 70 years old- survival time \> 3monts * Normal hemodynamic indices before the recruitment(including blood cell count and liver/kidney function ). For example: WBC\>4.0\*109/ L, NE\>1.5\*109/L, PLT\>100\*109/L, BIL\<1.5 times of upper limit of normal reference value, ALT and AST\<2.5 times of upper limit of normal reference value, and CRE\<1.2mg/dl * Good cardiac function before the recruitment, no seizure of myocardial infarction in past half years, and controllable hypertension and other coronary heart disease * Not concomitant with other uncontrollable benign disease before the recruitment(e.g. the infection in the kidney, lung and liver) * Not participating in other clinical trials before and during the treatment * Signed the Informed Consent Form * No peritoneal metastatic and CY0 in 28 days by laparoscopic exploration * Non-gastric stump cancer * No esophagus infiltrating or infiltrating less than 3cm
Exclusion criteria
* Distal metastasis to Mediastinal lymph node,liver ,peritoneal,pleural effusion ,ascites,above 16a2-b1 and others * Severe mental illness * Her-2 positive, desire for hercptin treatment * Ever administrated with other drugs(including TCM drugs) before the recruitment, or no guarantee of progress according to the study requirement after recruitment * Allergy to the drugs in this protocol * Pregnant and lactating women * Women at childbearing age and of pregnancy desire during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3 year OS | 3 years | The overall survival time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| radical resection rate | 4 months | the radical resection rates |
| 3 year DFS | 3 years | the diesease free survival time |
| 5 year OS | 5 years | The overall survival time |
| adverse events | 7months | number and degree of adverse events |
Countries
China
Outcome results
None listed